Efficacy of Remdesivir on Clinical Outcomes in COVID-19 Patients: A Study in a Tertiary Care Hospital in Pakistan.

Autor:	Shabbir B; Fatima Jinnah Medical University, Lahore, Pakistan., Malik U; King Edward Medical University, Lahore, Pakistan., Sarfraz Z; Fatima Jinnah Medical University, Lahore, Pakistan., Saeed F; King Edward Medical University, Lahore, Pakistan., Nawaz K; King Edward Medical University, Lahore, Pakistan., Khalid I; King Edward Medical University, Lahore, Pakistan., Gondal KM; Fatima Jinnah Medical University, Lahore, Pakistan.
Jazyk:	angličtina
Zdroj:	Journal of community hospital internal medicine perspectives [J Community Hosp Intern Med Perspect] 2024 May 07; Vol. 14 (3), pp. 25-31. Date of Electronic Publication: 2024 May 07 (Print Publication: 2024).
DOI:	10.55729/2000-9666.1333
Abstrakt:	Background: As of October 3, 2023, the global COVID-19 case tally exceeded 696 million, with almost 7 million fatalities. Remdesivir, approved for treatment of COVID-19 by regulatory bodies, has seen varying recommendations by the World Health Organization over time. Despite certain studies questioning its efficacy, others highlight potential benefits. The objective of this study was to gauge the impact of remdesivir on clinical outcomes in a Pakistani tertiary care hospital. Methods: An analytical cross-sectional study was conducted on 108 COVID-19 patients at Mayo Hospital Lahore between September 2020 and August 2021. Of these, 52 received remdesivir. The study employed a structured proforma for data collection, with analyses conducted using SPSS version 26, considering a p-value of less than 0.05 as statistically significant. Results: Demographic distribution between remdesivir-treated and untreated groups was similar. Significant improvement was observed in the remdesivir cohort in terms of oxygen saturation (58%), ferritin levels (58.2%), chest X-ray results (67.8%), and discharge rates (66.7%) when compared to the untreated group. Stratification based on disease severity showed that remdesivir was particularly beneficial for moderate illness cases in several parameters. Conclusion: This study suggests that remdesivir can be associated with improved outcomes, especially in patients with moderate COVID-19 severity. The data emphasizes the importance of the disease stage when considering therapeutic interventions and calls for more region-specific research to guide health responses amid diverse epidemiological landscapes. Competing Interests: Conflicts of interest: The authors declare no conflicts of interest in relation to this study. (© 2024 Greater Baltimore Medical Center.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu